易居(2048.HK)境外重組實質性完成,最終支持率82.04%
易居企業控股(02048.HK)8月1日發佈公吿,公司在開曼羣島計劃及香港計劃項下的重組程序已獲得正面支持。截至最終期限,公司境外債重組計劃已獲得約82.04%計劃債權人的支持。
易居於7月31日向香港高等法院提交有關展開香港計劃的原訴傳訊令狀,並於8月1日向開曼法院提交有關展開開曼計劃的尋求指令傳訊令狀及呈請。
按照市場慣例,獲得75%以上債權人支持是重組計劃的積極指標,符合進入法庭流程的要求。目前易居債權人支持率升至82.04%,並向香港及開曼法院提交呈請,這意味着,易居境外債務重組已實質性完成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.